KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Current Leases (2017 - 2026)

Amneal Pharmaceuticals has reported Current Leases over the past 9 years, most recently at $8.7 million for Q4 2025.

  • For Q4 2025, Current Leases rose 169.95% year-over-year to $8.7 million; the TTM value through Dec 2025 reached $8.7 million, up 169.95%, while the annual FY2025 figure was $8.7 million, 169.95% up from the prior year.
  • Current Leases for Q4 2025 was $8.7 million at Amneal Pharmaceuticals, up from $3.5 million in the prior quarter.
  • Over five years, Current Leases peaked at $10.3 million in Q3 2022 and troughed at $2.5 million in Q4 2023.
  • A 5-year average of $5.4 million and a median of $3.5 million in 2025 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: plummeted 77.62% in 2021 and later soared 297.91% in 2022.
  • Year by year, Current Leases stood at $9.7 million in 2021, then plummeted by 63.99% to $3.5 million in 2022, then decreased by 29.27% to $2.5 million in 2023, then soared by 30.16% to $3.2 million in 2024, then soared by 169.95% to $8.7 million in 2025.
  • Business Quant data shows Current Leases for AMRX at $8.7 million in Q4 2025, $3.5 million in Q3 2025, and $3.3 million in Q2 2025.